Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS

The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).

On March 26, 2026, Quantum BioPharma announced the appointment of leading multiple sclerosis specialist Dr. Salvatore Napoli as Principal Investigator for its planned Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in MS. The company plans to submit an IND to the U.S. Food and Drug Administration in the coming weeks, positioning Lucid-MS to enter mid-stage clinical testing and underscoring Quantum BioPharma’s strategic push into first-in-class, non-immunomodulatory MS treatments that could enhance its standing in the neurodegenerative disease market.

Lucid-MS, a first-in-class, non-immunomodulatory compound that has shown preclinical efficacy in preventing demyelination, is central to Quantum BioPharma’s growth strategy in MS and related neurodegenerative conditions. By securing an internationally recognized MS expert to lead the upcoming study, the company strengthens the clinical and scientific profile of the program, a move that could be significant for investors and patients if the Phase 2 trial demonstrates meaningful safety and efficacy outcomes.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Its lead asset, Lucid-MS (Lucid-21-302), is a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis, and it also holds economic interests in the consumer product UNBUZZD and a portfolio of secured strategic investments.

Average Trading Volume: 12,018

Technical Sentiment Signal: Sell

Current Market Cap: C$24.71M

See more data about QNTM stock on TipRanks’ Stock Analysis page.